DUNE MEDICAL DEVICES MARGINPROBE SYSTEM

by Dilon Medical Technologies  · Based in United States → — What if your cancer was removed in just one surgery?
General Surgery Oncology Pathology

Console: $50,000; disposable probe: $995 per procedure
Regulatory Status Disclosed

Overview

The DUNE MEDICAL DEVICES MARGINPROBE SYSTEM, developed by Dilon Medical Technologies, is an innovative intraoperative tissue assessment tool designed for use during breast-conserving surgery. It utilizes radiofrequency (RF) spectroscopy to provide real-time identification of cancerous tissue at the margins (≤ 1mm) of excised lumpectomy specimens. This technology aims to significantly improve surgeons’ ability to achieve clear margins in the initial operation, thereby reducing the need for repeat surgeries and improving patient outcomes. The system consists of a console and a disposable handheld probe that delivers RF signals to the tissue and analyzes the reflection, providing immediate visual and audible feedback to the surgeon.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Real-time intraoperative margin assessment
  • Utilizes radiofrequency (RF) spectroscopy
  • Identifies cancerous tissue at margins (u2264 1mm) of excised lumpectomy specimens
  • Reduces re-excision rates in breast-conserving surgery
  • Provides immediate feedback to surgeons (visible and audible output)
  • Comprised of a console and a disposable handheld probe
  • Non-invasive application on excised tissue
  • Effective in identifying both DCIS and invasive cancers (MarginProbe 2)
  • Features enhanced detection algorithms (MarginProbe 2)
  • User-friendly interface for seamless operating room integration

Use Cases

  • Intraoperative margin assessment during breast lumpectomy surgery
  • Reducing the need for repeat surgeries in breast cancer patients
  • Assessing margins for previously diagnosed breast cancer
  • Identifying cancerous tissue (including DCIS and invasive cancers) on the surface of excised breast tissue

What Physicians Need to Know

Key Capabilities
Provides real-time intraoperative assessment of surgical margins in breast-conserving surgery (lumpectomy) using radiofrequency (RF) spectroscopy to differentiate between malignant and normal breast tissue. The system offers visible and audible output for immediate feedback. MarginProbe 2 features increased sensitivity (over 76%) and allows for specific detection of DCIS or invasive cancer.
Clinical Utility
Significantly reduces re-excision rates in breast-conserving surgery, with studies showing over a 50% reduction in repeat procedures. It helps surgeons achieve clean margins during the initial surgery, improving patient outcomes and reducing the emotional and physical burden of additional operations. The device is effective for both invasive cancers and Ductal Carcinoma in Situ (DCIS).
Integration Options
Designed for easy integration into existing surgical workflows as an adjunctive diagnostic tool. It consists of a portable console unit and a sterile, single-use, hand-held probe. MarginProbe 2 is compatible with any hospital setting and integrates seamlessly into the operating room workflow.
Compliance Status
FDA approved (Premarket Approval for MarginProbe System in 2013, updated version 1.2 in 2015, and MarginProbe 2 in December 2025). It also complies with Restriction of Hazardous Substances (RoHS) requirements for sale in the European Union, where it has been available since 2008.
Pricing Model
The console has an approximate one-time cost of $50,000, and each disposable probe costs around $995 per procedure. Actual pricing may vary based on institutional contracts and volume discounts. The system offers potential cost savings to healthcare systems by reducing expensive re-excision surgeries.
User Experience
Features a user-friendly interface with a brighter screen, wider viewing angle, and improved on-screen notices. The MarginProbe 1.2 reduced in size and weight, and has a faster startup time of 90 seconds. Surgeons describe it as very user-friendly, straightforward to use, and having a short learning curve, adding minimal time to the procedure.
Support Quality
The updated design of MarginProbe 1.2 improved service time due to its reduced size. Older versions of the device remain fully supported.
Implementation Complexity
Considered easy to integrate into existing surgical workflows. The system requires surgeons to take multiple measurements on the excised specimen, a process that adds minimal time to the overall procedure. A training phase is typically involved for surgeons.
Evidence Base
Supported by robust clinical evidence, including FDA approval based on prospective, multicenter, randomized studies involving hundreds of patients. Pivotal trials demonstrated significant reductions in positive margins and re-excision rates. The MarginProbe platform has over 12 peer-reviewed publications, and studies indicate it is over three times more effective than traditional methods in identifying cancer on the margin. MarginProbe 2's pivotal study reported sensitivity over 76%.
Physician Tip

The MarginProbe System, particularly MarginProbe 2 with its enhanced detection algorithms, serves as a valuable *adjunctive* tool for real-time margin assessment in breast-conserving surgery. While it significantly reduces re-excision rates, remember it complements, rather than replaces, traditional histopathology. Be aware of the potential for false positives, which may lead to the removal of additional healthy tissue, but weigh this against the substantial benefit of reducing repeat surgeries and improving patient peace of mind. Leverage the immediate feedback to guide intraoperative decisions and strive for clear margins in the initial procedure.

The MarginProbe System is a self-contained medical device designed for direct use in the operating room. Its integration primarily involves fitting into the existing surgical workflow alongside standard methods like imaging and palpation. There are no explicit mentions of deep electronic medical record (EMR) or other hospital IT system integrations. Its portability and quick results facilitate its use within the current operating room environment. Dilon Technologies also offers other surgical devices, suggesting a potential for a complementary suite of tools within a surgical setting.

Details

Category Oncology AI, Surgical AI
Pricing Console: $50,000; disposable probe: $995 per procedure — Console: $50,000 (one-time cost); Disposable probe: $995 per procedure.
DeploymentOn-premise (console and probe used in the operating room)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The original MarginProbe System received Premarket Approval (PMA) from the FDA on December 27, 2012 (P110014). It is indicated as an adjunctive diagnostic tool for identifying cancerous tissue at the margins (≤ 1mm) of ex-vivo lumpectomy specimens during intraoperative use in patients undergoing lumpectomy for previously diagnosed breast cancer. Version 1.2 received FDA clearance in January 2015, and the next-generation MarginProbe 2 system received FDA approval and launched in the U.S. in December 2025.

Integrations
EHR Not specified
Specialties General Surgery, Oncology, Pathology

What the Web Says

The DUNE MEDICAL DEVICES MARGINPROBE SYSTEM, now part of Dilon Technologies, is an FDA-approved intraoperative tool designed to help surgeons identify cancerous tissue at the margins of excised breast tissue during lumpectomy procedures. It uses radiofrequency spectroscopy to provide real-time assessment, aiming to reduce the need for repeat surgeries. Physicians generally express positive opinions, highlighting its ability to improve surgical outcomes and provide peace of mind to both surgeons and patients.

Overall: Positive

Strengths

  • Significantly reduces re-excision rates in breast-conserving surgery, with studies showing reductions ranging from 51% to 75%.
  • Provides real-time, intraoperative margin assessment, allowing surgeons to make immediate decisions and remove additional tissue if needed.
  • Helps achieve clear margins in the initial lumpectomy, reducing patient anxiety and the emotional burden of repeat surgeries.
  • Can lead to less tissue removed overall by enabling targeted shaving of positive margins.
  • Effective for both invasive and DCIS (Ductal Carcinoma In-Situ) breast cancers.
  • User-friendly interface and compatible with any hospital setting.

Limitations

  • Can be expensive, with the system costing around $20,000 and each disposable probe approximately $1,000.
  • May produce false positives, leading to the removal of healthy tissue, which can have cosmetic implications.
  • Some studies indicate variability in diagnostic accuracy, with sensitivity ranging from 66.7% to over 90% and specificity from 47.5% to 87%.
  • Not universally adopted, and some institutions may have other methods for detecting cancer at the margins.
  • Long-term outcomes, such as recurrence rates, have not always been reported in studies.

Based on reviews from: Dilon Technologies, CURE, Globes English - u05d2u05dcu05d5u05d1u05e1, Healthcare Dive, PMC - NIH, FDA, BioSpace, Precedence Research, PR Newswire, INAHTA, YouTube, Imaging Technology News, eBay, accessdata.fda.gov, BJS | Oxford Academic

Last updated: 2026-07-17

Ratings & Reviews

Rate DUNE MEDICAL DEVICES MARGINPROBE SYSTEM

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Dilon Technologies Announces FDA Approval and U.S. Launch of MarginProbeu00ae 2, Next-Generation Intraoperative margin assessment technology
Dilon Technologies received FDA approval and launched its MarginProbeu00ae 2 system in the U.S., a next-generation device for real-time intraoperative margin assessment in breast cancer surgery. This new system aims to enhance precision during breast-conserving surgeries and reduce the need for repeat procedures.
2025-12
Precedence Research
Dilon Technologies Gains FDA Approval for MarginProbe 2
Dilon Technologies announced FDA approval and the U.S. introduction of its third-generation MarginProbe 2 system, which allows surgeons to determine the presence of cancerous tissue at the margins during breast-conserving surgery, potentially reducing repeat operations.
2025-12
Medical Device Network
FDA approves Dilon's intraoperative margin assessment device
The FDA approved Dilon Technologies' MarginProbe 2, a next-generation intraoperative margin assessment device for breast cancer surgery, which is designed to help surgeons decrease repeat procedures and improve patient outcomes.
2025-12
Dilon Technologies
Dilon Technologies Announces the Beginning of Enrollment in its Pivotal Trial of the Next Generation MarginProbeu2122 2 Used in Real-Time Margin Assessment
Dilon Technologies announced the enrollment of the first patient in its pivotal trial for the next-generation MarginProbeu2122 2, which is designed for real-time margin assessment during breast cancer surgery.
2024-02
BJS (British Journal of Surgery)
Reducing re-excision rates in breast conserving surgery with Margin Probe: systematic review
A systematic review found that the MarginProbeu00ae System is an effective intraoperative adjunct in breast-conservation surgery, reducing patient re-excision rates without adverse effects on breast cosmesis or increased excised tissue volume.
2023-11
European Journal of Surgical Oncology (EJSO)
The efficiency of MarginProbe in detecting positive resection margins in epithelial breast cancer following breast conserving surgery
A study evaluated the MarginProbeu00a9 in lumpectomy patients, finding a relatively low cancer detection rate and a high false-positive rate, which led to unnecessary tissue shavings in almost all patients.
2022-02
Dilon Technologies
Dilon Technologiesu00ae Inc. acquires the DuneMedical's MarginProbe
Dilon Technologies Inc. acquired substantially all assets of Dune Medical, including the MarginProbe, making Dilon the sole provider of the FDA-approved device for identifying positive margins during breast conservation surgery.
2020-04
FDA
DUNE MEDICAL DEVICES MARGINPROBE SYSTEM
The FDA's Premarket Approval (PMA) for the DUNE MEDICAL DEVICES MARGINPROBE SYSTEM was received on April 4, 2011, and approved on December 27, 2012.
2012-12

Videos

Product demos, reviews, and walkthroughs for DUNE MEDICAL DEVICES MARGINPROBE SYSTEM.

Loading videos...

View all on YouTube

Frequently Asked Questions

The MarginProbe System utilizes radiofrequency spectroscopy to analyze the electromagnetic 'signatures' of excised tissue specimens. A classification algorithm then compares these signatures to an internal library of known cancerous and non-cancerous breast tissues to provide real-time feedback on margin status. This algorithmic analysis helps surgeons identify malignant tissue at the surface of the specimen within minutes.
The MarginProbe System received Premarket Approval (PMA) from the U.S. FDA in 2013, with subsequent clearances for updated versions. Clinical trials have demonstrated that using MarginProbe can significantly reduce positive surgical margins and, consequently, the need for re-excision surgeries in breast-conserving procedures.
Studies have indicated that the MarginProbe System can have moderate sensitivity and, in some instances, poor specificity, leading to a potential for false-positive results. These false positives may result in the resection of healthy tissue, although some clinicians view this as a small price to pay for reducing re-operation rates. The device is also limited to use on the main lumpectomy specimen and not on shavings or within the lumpectomy cavity.
The MarginProbe console has a list price of approximately $50,000, with disposable probes costing around $995 per procedure, though actual pricing can vary based on negotiated contracts. While an upfront investment, the system aims to reduce the incidence of costly re-excision surgeries, which can range from $9,000 to $16,000 per procedure.
Alternatives to MarginProbe include traditional methods like intraoperative imaging, palpation assessment, and gross examination of the specimen. Another approach is the Full Cavity Shave (FCS), where additional margins are systematically removed from the lumpectomy cavity. These methods rely on visual, tactile, or imaging cues, whereas MarginProbe uses radiofrequency spectroscopy for tissue characterization.
The MarginProbe System is designed for intraoperative use as an adjunctive diagnostic tool, providing results within minutes while the patient is still in surgery. It requires the sterile disposable probe to be used on tissue specimens within 20 minutes of excision and is not intended to replace standard tissue histopathology assessment. Surgeons take multiple measurements across the specimen's surface to assess margins.

Related Tools

Visiopharm AI-driven Precision Pathology
Visiopharm
Oncology AI
Visiopharm provides AI-driven precision pathology software for research and diagnostics, offering image analysis applications for metastasis detection and biomarker evaluation.
DeepHeme
Memorial Sloan Kettering Cancer Center (developed in collaboration with UCSF and UC Berkeley)
Lab & Diagnostics
DeepHeme is an AI tool developed by Memorial Sloan Kettering Cancer Center, UCSF, and UC Berkeley that automates the counting and classification of blood and bone marrow cells to assist in the diagnosis of blood cancers, reducing manual review time and achieving expert-level accuracy.
ScreenPoint Medical
ScreenPoint Medical
Clinical Decision Support & Reference
ScreenPoint Medical offers Transpara, an AI-powered solution for breast cancer detection and diagnosis in mammography and digital breast tomosynthesis, designed to assist radiologists.
INIFY Prostate
ContextVision
Clinical Decision Support & Reference
INIFY Prostate is an AI-based decision support tool that accurately outlines suspicious prostate cancer areas in digitalized prostate biopsy samples.
Cartesion Prime (PCD-1000A/3) V10.21
Canon Medical Systems USA, Inc.
Clinical Decision Support & Reference
The Cartesion Prime (PCD-1000A/3) V10.21 is a premium, air-cooled digital PET/CT scanner from Canon Medical Systems, featuring AI-assisted deep learning reconstruction (AiCE) for superior image quality, faster scans, and reduced dose.
DERM (by Skin Analytics)
Skin Analytics
Clinical Decision Support & Reference
DERM is an AI as a Medical Device (AIaMD) with Class III CE mark that assesses dermoscopic images of skin lesions to provide a suspected diagnosis and referral recommendation, aiming to triage patients and reduce waiting times for skin cancer assessment.

See all Oncology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.